YOUR SEARCH FOR Text 165 RESULTS
71 of Total
Incyte Reports 2023 Third Quarter Financial Results and Provides Updates on Key Clinical Programs |
… results, and provides a status update on the Company’s clinical development portfolio. "Our … demand and enhanced payer coverage," said Hervé Hoppenot , Chief Executive Officer, Incyte . …
72 of Total
Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs |
… results, and provides a status update on the Company’s clinical development portfolio. "In … first quarter net pricing dynamics," said Hervé Hoppenot , Chief Executive Officer, Incyte . …
73 of Total
Corporate Governance | Incyte
… Committee Charters Audit & Finance Committee … Governance Committee Jean-Jacques Bienaimé Compensation Committee Nominating and …
74 of Total
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advance
… View all news Incyte Announces Positive CHMP … at 9:29 AM EST PDF Version Pending the European Commission decision, Zynyz ® (retifanlimab) in …
75 of Total
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a
… View all news Incyte Announces Positive Topline … doxorubicin, vincristine and prednisone) compared to R-CHOP alone as a first-line …
76 of Total
Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Derm
… View all news Incyte to Highlight Late-Breaking … Ruxolitinib Cream Improves Patient-Reported Outcomes in Adults With Moderate Atopic Dermatitis …
77 of Total
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativ
… View all news Incyte Announces New Positive … results from the STOP-HS program deliver compelling, long-term evidence supporting the …
78 of Total
Incyte to Report Fourth Quarter and Year-End 2025 Financial Results | Incyte
… View all news Incyte to Report Fourth Quarter and … with slides can be accessed at Investor.Incyte.com and will be available for replay for ninety …
79 of Total
Serving Patients Through Innovation | Incyte Stories
… May 24, 2023 Serving Patients Through Innovation At Incyte, our … our own terms and timelines versus relying on commercial manufacturing organizations and being …
80 of Total
… SCHEDULE 13G CUSIP No. 1 Names of Reporting Persons The Vanguard … Type of Reporting Person (See Instructions) IA Comment for Type of Reporting Person: On …